INS and endometrial cancer: Metformin upregulates progesterone receptors (making endometrium more sensitive to progesterone therapy), downregulates circulating insulin (insulin acts as growth factor for endometrial cancer cells), and inhibits proliferation and migration of endometrial cancer cells.